Merck Serono Commits € 1.2 million to the Grant for Fertility Innovation for 2015/16
Globally, six projects receive funding from this grant cycle
Launched in 2009, the GFI is dedicated to transforming innovative translational fertility research projects into concrete health solutions to improve the outcomes of assisted reproductive technologies (ART). In the last six years, approximately 750 applications to GFI were received from over 50 countries around the world; from this year’s applications, six projects from five countries were awarded a grant for a total of € 1.2 million.
“The GFI program fuels innovation and cutting-edge fertility research that has the potential to positively impact outcomes for couples - to further increase the success rate," said Dr. Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Drug Safety at Merck Serono. “We are excited by the growing number of high quality applications each year, reflecting significant opportunity for continued research and scientific advancement in fertility, where there is still unmet need.”
Every year, the GFI awardees are announced during a ceremony at ESHRE’s annual meeting. This year, six winning projects were announced during the ceremony:
- Clinical translation of a new procedure for embryo evaluation based on miRNAs profiling from spent blastocyst culture media: prospective multicenter study: Antonio Capalbo - Genera Reproductive Medicine centres, Rome (ITALY)
- Glycomarker Panel for Prediction of IVF Outcome: Tracey Edgell - Hudson Institute of Medical Research, Clayton (AUSTRALIA)
- Improved diagnostic of in-vitro-fertilization using miRNome and microvesicles from early stage embryos: Andreas Keller - Clinical Bioinformatics Center Saarland University, Saarbrücken (GERMANY)
- Embryo derived trypsin: A novel and simple marker of embryo viability: Nick Macklon - University of Southampton (UK)
- Identification of novel markers of human oocyte aging via non-invasive RNA sequencing analysis of cumulus cells: Pasquale Patrizio - Yale Fertility Center, New Haven (USA)
- Exoxomes/microvesicles release as a non-invasive method to assess embryo activity: Paola Vigano - San Raffaele Scientific Institute, Milan (ITA
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.